Physician profile
Timothy S Mitzel
NPI 1285656785
$3,622.80
in general payments reported to CMS, 2019-2025
21 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $296 · 2021: $1,074 · 2022: $661 · 2023: $416 · 2024: $470 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.84 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $379.42 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $369.87 | 2021-2025 | Trintellix |
| Alkermes, INC. | $365.96 | 2022-2025 | Lybalvi |
| Avanir Pharmaceuticals, INC. | $323.43 | 2019-2021 | |
| Allergan, INC. | $300.35 | 2019-2020 | |
| Lundbeck LLC | $281.43 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $114.94 | 2022-2024 | Austedo Xr, Uzedy |
| Eisai INC. | $102.19 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.67 | 2024-2025 | Caplyta |
| Corium, LLC | $90.72 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $85.67 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $75.22 | 2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $33.91 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.48 | 2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $21.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.74 | 2025 | Spravato |
| Aytu Biopharma, INC. | $16.02 | 2021 | |
| Almatica Pharma LLC | $15.67 | 2024 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $14.63 | 2019 | |
| Acadia Pharmaceuticals INC | $13.08 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mitzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.